Claim OwnershipThe Hematologist
Subscribed: 268Played: 2,183
Subscribe
© 2024 The Hematologist
Description
The Hematologist is the member newsletter of American Society of Hematology (ASH). It is designed for the broad constituency of ASH, all working toward the ultimate goal of conquering blood diseases. The Hematologist updates readers about important developments in the field of hematology and highlights what ASH is doing for its members.
141 Episodes
Reverse
In this episode, Contributing Editor Samuel Wilson, MD, an assistant professor of hematology at the University of North Carolina, Chapel Hill, talks with Marc Blondon, MD, an attending physician in the division of angiology and hemostasis with the University Hospitals of Geneva (Switzerland). They talk about a paper co-authored by Dr. Blondon titled, “Longitudinal profile of estrogen-related thrombotic biomarkers after cessation of combined hormonal contraceptives.” Dr. Wilson wrote about the study in a recent issue of The Hematologist.
In this episode, Editor-in-Chief Shaji Kumar, MD, a professor of medicine at Mayo Clinic in Rochester, Minnesota, talks with Leslie Ellis, MD, a professor of internal medicine at Atrium Health Wake Forest Baptist in Winston Salem, North Carolina. They discuss the ASH Ambassador Program, which is designed to support the recruitment and retention of trainees into hematology. Dr. Ellis is chair of an ASH oversight subcommittee for that program.
In this episode, Tamara Dunn, MD, a clinical associate professor of medicine in the division of hematology at Stanford University in Stanford, California, and co-chair of ASH’s Women in Hematology Working Group, hosts a conversation with Toyosi Onwuemene, MD, an associate professor of medicine, specializing in hemostasis/thrombosis, at Duke University in Durham, North Carolina, and Nina Shah, MD, the global clinical head for multiple myeloma research and development at AstraZeneca. They talk about career choices and opportunities for women in hematology, both in academic medicine and industry. Support for this episode provided by Sanofi.
In this episode, Contributing Editor Ajai Chari, MD, a professor of clinical medicine and director of the myeloma program at the University of California San Francisco, talks with Pieter Sonneveld, MD, PhD, a professor of hematology at the Erasmus University of Rotterdam in the Netherlands. They discuss Dr. Sonneveld’s recent paper, “Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma,” published in The New England Journal of Medicine. Dr. Chari wrote about Dr. Sonneveld’s paper in The Hematologist with his Diffusion article, “Four Is Better Than Three: Will We Finally Agree?” Disclosures: Dr. Chari has received consulting fees from Abbvie, Adaptive, Amgen, Antengene, Bristol Myers Squibb, Forus, Genentech/Roche, Glaxo Smith Klein, Janssen, Karyopharm, Millenium/Takeda, and Sanofi/Genzyme and received research funding from Janssen. Dr. Sonneveld has served on the advisory board of Pfizer and has received research funding and served on the advisory boards of Amgen, Bristol Myers Squibb, Celgene, Janssen, and Karyopharm.Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/
In this episode, Contributing Editor Lori Muffly, MD, an associate professor of medicine specializing in blood and marrow transplantation and cellular therapies at Stanford University in California, talks with Roberta Demichelis, MD, an assistant professor in the department of hematology and oncology at the Salvador Zubirán National Institute of Health Sciences and Nutrición in Mexico City. They discuss access to care for patients with acute lymphoblastic leukemia in low- and middle-income countries, especially among Hispanic populations. Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/
In this episode, Contributing Editor Sarah Tasian, MD, associate professor at the University of Pennsylvania School of Medicine and chief of the hematologic malignancies program at the Children’s Hospital of Philadelphia, talks with Rob Pieters, MD, the chief medical officer at the Princess Maxima Center for Pediatric Oncology and professor of pediatric oncology at the University of Utrecht, both in Utrecht, Netherlands. Dr. Pieters is one of the authors of a paper published recently in The New England Journal of Medicine: “Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia.”Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/
In this episode, Dr. Shaji Kumar, editor-in-chief of The Hematologist, has a conversation with Drs. Jonathan Licht and Keith McCrae, the editors-in-chief, respectively, of ASH's two new journals Blood Neoplasia and Blood Vessels, Thrombosis & Hemostasis.Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/
In this episode, Dr. Satiro De Oliveira talks about his own experience with the mentorship program within ASH’s Minority Recruitment Initiative and its impact on trainees coming from underrepresented groups. Dr. De Oliveira is an associate professor in the Division of Pediatric Hematology Oncology at UCLA.Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/
In this episode, Contributing Editor Kate Markey, MBBS, PhD, talks with Shernan Holtan, MD, one of the authors of a paper published recently in The New England Journal of Medicine: “Post-transplantation Cyclophosphamide-based Graft-versus-host Disease Prophylaxis.”Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/
In this episode, Contributing Editor Dr. Robert Hasserjian has a conversation with Dr. Siddhartha Jaiswal about a recent paper Dr. Jaiswal co-authored: “Aberrant activation of TCL1A promotes stem cell expansion in clonal haematopoiesis.” Dr. Hasserjian is a professor of pathology at Harvard Medical School. He is also the director of the Hematopathology Fellowship Program at Massachusetts General Hospital. Dr. Jaiswal is an assistant professor of pathology at Stanford University School of Medicine. Dr. Hasserjian wrote about Dr. Jaiswal’s paper in his recent Diffusion article in The Hematologist. You can access his Diffusion article online at: https://ashpublications.org/thehematologist/article/doi/10.1182/hem.V20.4.202344/496652/Genetic-Background-Influences-the-Growth-of-CHIP Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/
In this episode, Drs. Robert Stern and Ronak Mistry talk about their own professional journeys as hematologists, why they love what they do, the medical education for hematologists, and recruitment efforts to bring more students into the field.Dr. Stern is the associate program director with the Dana-Farber Massachusetts General Brigham Fellowship in Hematology and Oncology in Boston. Dr. Mistry is a clinical fellow in the division of hematology and oncology at Vanderbilt University Medical Center in Nashville.Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/
In this episode, Contributing Editor Dr. Michael Scott is joined by Dr. Sumedha Arya for a conversation with Dr. Cindy de Jong. They discuss a study covered by Drs. Scott and Arya in their recent Diffusion article titled “Anticoagulation and Abnormal Uterine Bleeding: Acknowledging Calls to Action.” Dr. de Jong performed analysis for the study and served as one of the lead authors of the paper published in Blood. To access the Diffusion article online, please click here. Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/
In this installment, Dr. Nicole Gormley and Dr. Grzegorz Nowakowski discuss a collaboration between ASH and the FDA that led to a successful workshop on regulatory science in hematology, an event they co-chaired and one that will return Oct. 10–11 at ASH headquarters in Washington, D.C. Dr. Gormley, a hematologist with the FDA, is the Division Director for the Division of Hematologic Malignancies 2 and the Acting Associate Director for Oncology Endpoint Development within the Oncology Center of Excellence. Dr. Nowakowski is a hematologist at the Mayo Clinic Rochester where he serves as the Deputy Cancer Center Director for Clinical Research. Dr. Nowakowski also serves as Chair of the ASH Subcommittee on Clinical Trials.Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/
In this installment, Contributing Editor Dr. Loretta J. Nastoupil has a conversation with Dr. Michael Dickinson. They discuss the New England Journal of Medicine article covered by Dr. Nastoupil in her most recent Diffusion article titled, “The Next Wave of T-cell Engagement for the Management of Diffuse Large B-cell Lymphoma.” In the article, Dr. Nastoupil discusses a study that looks at a promising therapy for the management of diffuse large B-cell lymphoma. Read more Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/
Nesta segunda parte de nossa serie sobre a adaptação das Diretrizes de Prática Clínica da ASH sobre tromboembolismo venoso na América Latina, Dra. Suely Meireles Rezende e Dr. Daniel Días Ribeiro discutem a publicação das diretrizes para prevenção de tromboemboilsmo venoso em pacientes na América Latina. Este podcast é a versão em português de uma série especial com episódios em inglês, espanhol e português. Daniel Días Ribeiro, Médico hematologista e Patologista Clínico, Mestre e Doutor pela Faculdade de Medicina – UFMG, Doutor em Epidemiologia Clínica pela Leiden University Medical Center. Dr. Suely Meireles Rezende, Médica hematologista, Professora associada da Faculdade de Medicina da universidade federal de Minas Gerais, representando a Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular.Nossos participantes declararam não ter conflito de interesse com empresas que fabricam e vendem medicamentos ou dispositivos para diagnosticar ou tratar tromboemboilsmo venoso.Visite www.hematology.org/vte para obter mais informações sobre as diretrizes.Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/
En este episodio de nuestra serie sobre las Guías de Práctica Clínica de ASH, la Dra. Pamela Zuñiga y el Dr. Pedro Pablo García Lázaro Guillermo conversan sobre la importancia clínica de las nuevas Guías de ASH para el Manejo del Tromboembolismo Venoso para América Latina. Este podcast es la versión en español de una serie especial de tres partes con episodios en inglés, español, y portugués.La Dra. Pamela Zuñiga es hematóloga en la Pontificia Universidad Católica de Chile y participante del Panel LATAM ASH VTE en representación de la Sociedad Chilena de Hematología.El Dr. Pedro Pablo García Lázaro es hematólogo en la Universidad Privada Antenor Orrego y el Hospital Especializado Víctor Lazarte Echegaray, y participante del Panel LATAM ASH VTE en representación de la Sociedad Peruana de Hematología.Nuestros participantes han declarado que no tienen conflicto de interés financiero directo alguno con compañías que desarrollan y venden drogas o dispositivos para diagnosticar o tratar tromboembolismo venoso. Visite www.hematology.org/vte para obtener más información sobre las guías.Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/
In this installment of our ASH Clinical Practice Guidelines series, Dr. Luis Meillon and Dr. Jaime Pereira have a conversation about the clinical importance of new ASH Guidelines on Venous Thromboembolism in Latin America. This podcast is the English version of a dedicated three-part series in English, Spanish, and Portuguese. Dr. Luis Meillon is a hematologist at the ABC Medical Center and panel member representing the Sociedad Mexicana de Trombosis y Hemostasia. He is President of the Agrupación Mexicana para el Estudio de la Hematología. Dr. Pereira is Professor at the Department of Hematology-Oncology, School of Medicine, Catholic University of Chile and member of the Latin American panel for ASH VTE Guidelines on behalf of the Chilean Society of Hematology.None of our speakers has a direct financial conflict of interest with companies that market drugs or devices used to diagnose or treat VTE.For more information on ASH Guidelines, and how you can get involved, visit www.hematology.org/guidelines. Send in your comments to quality@hematology.org. Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/
In this installment, 2023 ASH Summit on Immunotherapies for Hematologic Diseases co-chair Dr. Terry Fry, and The Hematologist Editor-in-Chief Dr. Shaji Kumar have a conversation about what attendees can expect for this year’s summit, taking place in-person only. They discuss the current progress of immunotherapies for treating hematologic malignancies, some of the limitations to bringing these kinds of therapies to patients, manufacturing and regulatory issues, management of toxicities, and more, all to be specifically addressed during the summit. Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/
In this installment, The Hematologist Editor-in-Chief Dr. Shaji Kumar has a conversation with Contributing Editor Dr. Saad Usmani. They discuss Dr. Usmani’s Year’s Best coverage in which he describes the past year’s breakthroughs in immunotherapies for multiple myeloma. The focus in particular on B-cell maturation antigen (BCMA) –targeted therapies, including chimeric antigen receptor T-cells (CAR-Ts) and bispecific T-cell engagers. The editors discuss data presented as recently as the 2022 ASH Annual Meeting, as well as issues surrounding toxicity, patient relapse, and the future of bispecifics and CAR-Ts.You can access his article online athttps://ashpublications.org/thehematologist/article/doi/10.1182/hem.V20.1.202314/494129/GPRC5D-The-Next-Frontier-for-Immunotherapy-inMusic: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/
In this installment, Contributing Editor Dr. Lori Muffly has a conversation with Dr. Partow Kebriaei. They discuss the Blood article covered by Dr. Muffly in her most recent Diffusion article titled, “Should Minimal Residual Disease Guide the Way? The Evolving Role of Allogeneic Hematopoietic Cell Transplantation for Adults With Ph+ Acute Lymphoblastic Leukemia in First Complete Remission.” In the article, Dr. Muffly explored the study by Drs. Ghobadi, Kebriaei, and colleagues, which examined the impact of allogeneic hematopoietic cell transplantation in adults with Ph+ acute lymphoblastic leukemia achieving deep molecular remission.You can access his Diffusion article online at https://ashpublications.org/thehematologist/article/doi/10.1182/hem.V19.6.202267/486876/Should-Minimal-Residual-Disease-Guide-the-Way-The.Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/
Comments
Download from Google Play
Download from App Store
United States